Tiger Brokers

Lucid Diagnostics FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million

Reuters
Yesterday
<a href="https://laohu8.com/S/LUCD">Lucid Diagnostics</a> FY2025 operating loss widens to $58 million; revenue rises 9.3% to $4.7 million
  • Lucid Diagnostics published its annual report on Form 10-K for the fiscal year ended Dec. 31, 2025.
  • Reported revenue of USD 4.7 million, up 9.3%, driven mainly by higher consideration received for EsoGuard tests.
  • Cost of revenue was USD 6.7 million, down 5.6%, primarily reflecting lower manufacturing costs for EsoCheck devices and EsoGuard tests.
  • Net loss was USD 58.0 million.
  • Cash used in operations was USD 46.5 million.
  • Ended the year with cash on hand of USD 34.7 million.
  • Financing activities provided USD 59.0 million.
  • Business updates included an 18-month real-world analysis covering about 12,000 patients.
  • Business updates also included a U.S. Department of Veterans Affairs contract award for EsoGuard.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lucid Diagnostics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001437749-26-009805), on March 25, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10